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ABSTRACT
Epigenetic regulation plays an essential role in tumor development and epigenetic 
modifiers are considered optimal potential druggable candidates. In order to identify 
new breast cancer vulnerabilities and improve therapeutic chances for patients, we 
performed in vivo and in vitro shRNA screens in a human breast cancer cell model 
(MCF10DCIS.com cell line) using epigenetic libraries. Among the genes identified 
in our screening, we deeply investigated the role of Chromodomain Helicase DNA 
binding Protein 4 (CHD4) in breast cancer tumorigenesis. CHD4 silencing significantly 
reduced tumor growth in vivo and proliferation in vitro of MCF10DCIS.com cells. 
Similarly, in vivo breast cancer growth was decreased in a spontaneous mouse 
model of breast carcinoma (MMTV-NeuT system) and in metastatic patient-derived 
xenograft models. Conversely, no reduction in proliferative ability of non-transformed 
mammary epithelial cells (MCF10A) was detected. Moreover, we showed that CHD4 
depletion arrests proliferation by inducing a G0/G1 block of cell cycle associated 
with up-regulation of CDKN1A (p21). These results highlight the relevance of genetic 
screens in the identification of tumor frailties and the role of CHD4 as a potential 
pharmacological target to inhibit breast cancer growth.
INTRODUCTION
Loss of function shRNA screening has become an 
invaluable tool in cancer research since this approach 
allows the identification of new genes essential in cancer 
maintenance and growth [1–20]. A variety of screens have 
been performed in different tumor types, some of which 
has lead to the identification of previously uncharacterized 
oncogenes that can be now considered potential candidates 
for targeted therapies [16].
Breast cancer is a heterogeneous disease, which displays 
diverse biological characteristics, clinical behavior and 
response to treatment [21]. In the context of this malignancy, 
the discovery of new therapeutic targets is essential since it 
remains the leading cause of cancer death among females 
worldwide. Epigenetic factors, mediating reversible changes 
at chromatin level, can regulate tumorigenesis, plasticity 
and heterogeneity of breast cancer cells [22–24], so that 
effective benefits of epigenetic-targeted therapy are currently 
investigated to obtain new-generation drugs [25].
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The Mi-2/nucleosome remodeling and deacetylase 
(NuRD) complex regulates the transcription of genes 
involved both in normal development and in tumorigenesis, 
by modifying the chromatin structure through the activity 
of histone deacetylases [26, 27]. It has been recently shown 
that several members of the NuRD complex (RbAp46, 
HDAC1, 2 and MTA1-3) stimulate breast cancer formation 
and metastases dissemination by interacting with steroid 
receptors, growth factor receptors, and other cell-type 
specific transcriptional pathways [28–32]. Another member 
of the NuRD complex, the Chromodomain Helicase DNA 
binding Protein 4 (CHD4), has been shown to activate 
cell cycle transition and DNA-damage responses through 
distinct mechanisms [33–35]. However to date, the role 
of CHD4 in breast cancer progression has been poorly 
investigated.
Here, we used a human breast cancer cell line 
(MCF10DCIS.com), known for its capability of 
recapitulating the various stages of the malignancy when 
transplanted in an immune-compromised host [36] to 
perform an RNAi screen in vivo and in vitro. MCF10DCIS.
com cells are endowed with metastatic potential and their 
tumorigenic features have been extensively characterized 
in vivo and in vitro [14, 36]. We applied a conventional 
RNAi screen to identify epigenetic vulnerabilities in 
breast cancer. To this end, an shRNA, lentiviral-based 
library composed of chromatin modifiers has been used, as 
previously described [1], and CHD4 identified as a crucial 
gene in breast cancer development. We demonstrated 
that CHD4 silencing inhibits tumor growth in vivo and 
proliferation in vitro by strongly reducing cell cycle 
progression in xenografts of MCF10DCIS.com cells, in 
transgenic, HER2-activated, mouse model and in patient-
derived xenografts (PDX) of breast cancer.
RESULTS
In vivo and in vitro shRNA screens in a human 
breast cancer cell line
To identify novel genes that sustain breast cancer 
growth, we performed loss of function in vivo and in vitro 
shRNA screens of epigenetic regulators in a human breast 
cancer cell line (MCF10DCIS.com). To investigate which 
epigenetic modifiers favor breast cancer growth, we used 
two custom pooled, barcode (BC)-coupled shRNA libraries 
composed of 1204 and 1192 shRNAs (hEpi1 and hEpi2, 
respectively), targeting 236 epigenetic regulators (118 in 
hEpi1 and 118 in hEpi2, see Materials and Methods for 
details) and four control genes (Luciferase - LUC, KIF11, 
PSMA1 and RPL30, Supplementary Table S1) that were 
successfully used in an in vivo RNAi screen in melanoma 
[1]. MCF10DCIS.com cells were independently infected 
with the two libraries at low multiplicity of infection 
(MOI=0.2) so that each cell conceivably carried one single 
viral integrant. Ten different shRNAs were used to silence 
each gene. Transduced cells were either orthotopically 
injected into the mammary gland of immunodeficient 
mice (in vivo screen, 1.2^106 cells/animal, four mice per 
replicate) or cultured in vitro (in vitro screen, 1.2^106 
cells/plate in duplicate), so that 1000 cells represented 
each single shRNA (Figure 1A).
Genomic DNAs extracted from transduced cells 
(reference), in vitro cultured cells and tumors grown 
in vivo were subjected to PCR amplification and Next 
Generation Sequencing (NGS) for barcodes (BCs) 
quantification, as previously described [1] (Figure 1A). In 
the library, each shRNA was univocally associated to a 
single BC.
We first analyzed the shRNA frequency and 
distribution in four tumors grown in vivo. Almost all 
shRNAs (around 98%) were recovered in the analyzed 
samples (data not shown) and the shRNA log2 frequency 
(f) showed high correlation between replicates (R> 0.71 
for hEpi1 and R> 0.68 for hEpi2), suggesting that each 
tumor can represent the complexity of the whole library 
(Supplementary Figure S1A, S1B). We then compared 
the relative frequency of each shRNA per tumor to its 
respective reference and we calculated the log2 fold 
change (FC) of each library. The resulting distribution 
curves were shifted toward negative values (data not 
shown), suggesting that the epigenetic libraries exerted 
an inhibitory effect on in vivo breast cancer growth. To 
identify depleted genes (hits), we calculated the average 
of the z-score of the log2 FC of every single shRNA in the 
four tumors and assessed the distribution of the z-score 
values. We then considered depleted those shRNAs whose 
z-score value was equal or below the median of the curve 
and counted shRNAs depleted per gene (i.e. observed 
genes, Supplementary Figure S1C, S1D). To determine 
the minimum number of depleted shRNAs needed to 
score the hits and minimize the number of false positives, 
we applied a hypergeometric distribution, inferring the 
probability to find, on a set of 10 shRNA per gene (i.e. 
expected genes, Supplementary Figure S1C, S1D), the 
shRNAs scoring equal or below the median by chance 
(P=0.5) 0 to 10 times. We found that the “observed 
genes” overcome the “expected genes” when the depleted 
shRNAs are either 7 (hEpi1) or 8 (hEpi2) (Supplementary 
Figure S1C, S1D). To select candidate hits, we decided 
to set the cut-off threshold at 7 depleted shRNAs per 
gene (70% of the targeting shRNAs). We applied the 
same analysis to a pool of the above-mentioned tumors, 
and we observed that the resulting gene list corresponded 
well to that obtained by analyzing single tumors (data not 
shown), indicating that we can analyze tumors in pool. In 
order to obtain a biological triplicate, we sequenced and 
analyzed two more pools (4 tumors each). The scatter plots 
representing the shRNAs log2 (f) showed high correlation 
values among the in vivo pool replicates, ranging from 
R=0.82 (Figure 1B, upper panel for hEpi1) and R=0.75 
(Figure 1B, lower panel for hEpi2), indicating a good 
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experimental reproducibility even in a high heterogeneous 
system such as breast cancer. The log2 (FC) distributions 
of the shRNAs in the tumor pools (mean of biological 
triplicate) were shifted toward negative values, as 
expected (Figure 1C upper panel hEpi1 and lower panel 
hEpi2, respectively). Similarly, NGS analysis of the in 
vitro screen showed full representation of the libraries and 
a perfect correlation between the shRNA log2 (f) of the 
in vitro samples (R=0.99: Figure 1D, upper panel hEpi1 
and lower panel hEpi2). The log2 (FC) distribution of the 
shRNAs in the in vitro duplicates (mean of replicates) 
followed a symmetrical distribution, as shown in 
Figure 1E (upper panel hEpi1 and lower panel hEpi2).
We generated a final list of candidate hits, considering 
depleted those genes whose single shRNA z-score values 
(70% of shRNAs per gene) were equal or below the median 
among the z-score distribution of triplicate pools in vivo 
or duplicates in vitro. The resulting list of depleted genes 
was composed of 50 and 51 genes (in vivo and in vitro 
respectively), 29 of which were in common between 
the two experimental conditions (Figure 1F). Notably, the 
positive control genes (KIF11, PSMA1, RPL30) and the 
neutral control (LUC) included in the epigenetic libraries 
scored as expected (Supplementary Table S1).
Enrichment analysis of breast cancer hits reveals 
gene involvement in cell cycle regulation
We analyzed the list of the commonly depleted hits 
in the in vivo and in vitro settings by means of Ingenuity 
Figure 1: In vivo and in vitro shRNA screening using a human breast cancer cell line (MCF10DCIS.com). A. Graphical 
representation of the experimental procedure: MCF10DCIS.com cells were infected with hEpi1 and hEpi2 libraries and then orthotopically 
transplanted in the 4th mammary gland of NOD/SCID mice (in vivo screen), or cultured in vitro for 21 days (in vitro screen). Genomic DNAs 
(gDNAs) were extracted from transduced cells as reference, tumors and in vitro cultures and subsequently subjected to PCR amplification 
and Next Generation Sequencing (NGS) to quantify shRNAs representation. B. Scatter plot representation of the shRNAs log2 frequencies 
(f) of two different pools (pool tumors 1 and 2) composed of four tumors each of hEpi1 (upper panel) and hEpi2 (lower panel) transduced 
cells. Black dotted lines represent the axis bisectors. Pearson correlation coefficient (R) indicates the similarity between the two samples. 
C. Distribution of the shRNA reads expressed as log2 Fold Change (FC) in the three pooled samples (mean of replicates) in hEpi1 (upper 
panel) and hEpi2 (lower panel) samples. D. Scatter plot representation of the shRNAs log2(f) of in vitro duplicates of hEpi1 (upper panel) 
and hEpi2 (lower panel) libraries. Black dotted lines represent the axis bisectors. Pearson correlation coefficient (R) indicates the similarity 
between the two samples. E. Distribution of the shRNA reads expressed as log2(FC) of two in vitro samples (mean of replicates) of hEpi1 
(upper panel) and hEpi2 (lower panel) transduced cells. F. Venn diagrams reporting the number of genes scoring as depleted targets 
in vivo, in vitro and in common between the two settings. G. Protein interaction network of 15 out of 29 genes scoring by Ingenuity 
Pathway Analysis and significantly enriched for “Cell cycle” regulation analyzed in STRING. Line thickness represents the strength of data 
confidence. Encircled genes were selected for in vivo and in vitro validation of the screen.
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Pathway Analysis (IPA) and Molecular Signature Data Base 
(MSigDB) software to investigate if common pathways 
involved in tumorigenesis can be highlighted. IPA revealed 
that 27 genes (out of the 29 common genes) participated 
in the “cancer” signature (p-values: 4.96E-02 – 2.87E-05), 
which is consistent with the role of epigenetic targets in 
research and clinical practice. 15 out of 29 genes scored as 
significantly enriched in the “Cell cycle” regulation (BAZ1B, 
BPTF, BRD4, CHAF1A, CHD1L, CHD4, EHMT1, PCNA, 
PLK1, PRMT5, SMC1A, SMC2, SMC3, SMC4, UBE2I) 
(p-values: 4.13E-02 – 7.61E-09) (Supplementary Table S1) 
or “DNA replication, recombination and repair” (BAHD1, 
BAZ1B, BPTF, BRD4, CHAF1A, CHD1L, CHD4, EHMT1, 
PCNA, PLK1, SIRT5, SMC1A, SMC2, SMC4, UBE2I) 
(p-values: 4.05E-02 – 7.61E-09) signatures (Supplementary 
Table S1). Genes network representation of cell cycle 
regulators in STRING revealed high confidence connections 
between the majority of the hits (Figure 1G). MSigDB 
analysis confirmed the implication of our candidate hits 
in “Cell cycle related targets of E2F transcription factors” 
(p-value: 2.19E-9), “G2/M checkpoint” (p-value: 2.19E-9) 
and “Mitotic spindle assembly” (p-value: 6.57E-6) 
(Supplementary Table S1). Our newly identified candidate 
hits show a critical role in cell cycle regulation, and their 
modulation promotes the development of different types of 
cancer [33, 37–39], breast cancer in particular [40–44].
In vivo and in vitro validation of the RNAi screens
In order to validate the in vivo and in vitro 
screens, we selected four candidates among the genes 
highly and concordantly depleted in the two screens 
(Supplementary Table S1). Bromodomain Adjacent to 
Zinc finger domain 1B (BAZ1B), Bromodomain PHD 
finger Transcription Factor (BPTF), Bromodomain 
containing 4 (BRD4) and CHD4 are key components 
of various epigenetic complexes implicated in cancer 
growth, progression and/or metastasis formation [32, 
37, 45–50]. MCF10DCIS.com cells were independently 
infected with two pooled shRNAs of the four candidates 
(shRNA#1 and #2) or control shLUC. Silencing efficacy 
was measured using western blot analysis, as shown 
in Supplementary Figure S2A. Transduced cells were 
orthotopically transplanted in the mammary gland of 
NOD/SCID mice and tumor growth evaluated (in vivo 
validation). Depletion of each target significantly 
reduced (60-90%) the size of the tumors, as compared 
to control (Figure 2A), suggesting that all candidates 
have an oncogenic role in breast cancer. To validate our 
screening in vitro, shRNA-infected MCF10DCIS.com 
cells were analyzed for cell proliferation, migration and 
clonogenic abilities, all in vitro features associated with 
aggressiveness and metastatic potential [51]. Silencing of 
each gene caused a strong decrease of cell proliferation 
(40-70%) (Figure 2B), a robust reduction of migratory 
ability (60-80%) (Figure 2C), and a significant drop in the 
clonogenic capability (60-90%) of the cells (Figure 2D). 
Taken together, these results provide a robust validation of 
our screens, both in vivo and in vitro, suggesting that all 
selected hits are required for breast cancer growth.
CHD4 sustains tumor growth in murine and 
human breast cancer models
CHD4 is a core component of the nucleosome 
remodeling and histone deacetylase NuRD complex, 
whose function can be exploited in combination with the 
other proteins of the NuRD complex, as well as alone 
[52]. To better uncover the role of CHD4 in breast cancer 
maintenance, we chose the MMTV-NeuT transgenic 
mouse model that closely reflects some features of the 
aggressive human G3 breast cancer and of the human 
HER2 positive (+) tumors [53, 54]. Cells derived from the 
dissociation of spontaneously growing mammary tumors 
were infected using two pooled shRNAs targeting Chd4 
or control scramble (SCR) shRNAs and then transplanted 
into syngeneic mice. CHD4 protein levels were assessed 
at day 0 and 8 upon infection (at the beginning and the end 
of the proliferation assay) (Supplementary Figure S2B). 
Chd4 silencing significantly reduced (about 67%) tumor 
growth in vivo (Figure 3A). As for the human cell line, we 
investigated the effect of Chd4 inhibition on in vitro cell 
proliferation and migration (Figure 3B, 3C). Remarkably, 
knockdown of Chd4 significantly reduced MMTV-NeuT 
cell growth (45%) and cell migration (46%) compared 
to the control (Figure 3B, 3C), confirming that CHD4 is 
implicated in the development of HER2+ breast cancer, 
independently of the immunological context.
To investigate the effect of CHD4 in a preclinical 
context, we developed a human metastatic breast cancer 
(MBC) model by direct implantation of patient-derived 
tumor tissue into the mammary fat pad of NSG mice to 
obtain a xenograft model (PDX). PDX cells were then 
serially transplanted and also grown in culture to obtain 
short-term human cultures. PDX tumors were stained for 
the most common prognostic markers, i.e. Estrogen (ER), 
Progesterone (PgR), HER2 receptors and Ki67, to assess 
the epithelial origin of the tumor, its correspondence with 
the patient tissue and its proliferative index (Figure 3D). 
PDXs phenotypically recapitulated the heterogeneity of the 
patient tumor (manuscript in preparation) and maintained 
their subtype classification (MBC2 is a Triple Negative and 
MBC22 and MBC18 are Luminal B breast cancers). Cells 
derived from dissociation of PDX tumors were infected 
with a pool of shRNAs targeting CHD4 or neutral control 
(shLUC), analyzed for silencing efficacy (Supplementary 
Figure S2C) and then re-transplanted in NSG mice. 
Notably, CHD4 silencing significantly reduced in vivo 
growth (80%) (Figure 3E), confirming the role of CHD4 
in growth maintenance of two different metastatic breast 
cancer subtypes and suggesting that CHD4 can be a potential 
druggable target also for the most aggressive diseases.
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In order to evaluate the effects of CHD4 inhibition 
on normal tissues, we studied CHD4 silencing on 
the MCF10A human mammary epithelial cell line, 
representing the non-transformed counterpart of the 
MCF10DCIS.com cells, lacking tumorigenic potential 
in vivo and invasiveness in vitro [55]. MCF10A cells 
were efficiently silenced for CHD4 (Supplementary 
Figure S3A) and transduced cells plated for in vitro 
assays, as done for the corresponding MCF10DCIS.
com cancer cells. Silencing of CHD4 did not 
significantly reduce proliferation (Supplementary 
Figure S3B), migration ability (Supplementary Figure 
S3C) and clonogenic potential (Supplementary Figure 
S3D), suggesting that depletion of CHD4 should be 
likely effective in a cancer-specific context without 
influencing the biological and cellular functions of 
normal tissues.
CHD4 controls breast cancer cell cycle 
progression
CHD4 knock-down can induce cell cycle arrest 
due to CDKN1A up-regulation in a TP53 -dependent 
[33] or -independent manner [32], suggesting that 
it can differently regulate cell functions according 
to the biological context. To investigate CHD4-
correlated mechanisms underlying the regulation of cell 
proliferation in breast cancer, we decided to examine the 
cell cycle progression of CHD4-silenced MCF10DCIS.
com cells. Flow cytometric analysis revealed that 
CHD4-knock-down cells prevalently accumulate in 
the G0/G1 phase of the cell cycle (73%) compared to 
control cells (57%), with a consistent reduction of the 
cell population in the S phase (15% in shCHD4 cells 
vs 27% in shLUC) (Figure 4A). Cell cycle deregulation 
Figure 2: Validation of the shRNA screens. MCF10DCIS.com infected with two pooled shRNAs targeting the indicated genes were 
used for in vivo A. and in vitro B. validation. A) Transduced cells were transplanted in NOD/SCID mice. Box plots represent tumor volume 
(mean±SD - cm3) of five to eight distinct tumors grown in vivo. B) Growth curves of shRNAs-infected cells were constructed calculating 
the relative proliferation values (mean±SD) expressed as ratio of the mean luminescent values in the shRNA expressing cells compared to 
the control (shLUC) at time of plating (Day 0). Relative migration (mean±SD) C. and relative colony formation D. expressed as a ratio of 
silenced versus control (shLUC) values, were calculated by ImageJ analysis. Statistical significances were calculated by applying the one-
way ANOVA test followed by Dunnet’s post-hoc test (**: P<0.01; ***: P<0.001).
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is one of the hallmark of cancer, occurring through the 
alteration of proteins that influence cell cycle progression 
at different levels [56]. CHD4 can stimulate a number 
of cell cycle regulators, including cyclins implicated in 
the G1/S transition or mitosis (cyclin A2, B1 and E2) 
and in the G1 phase activity (cyclin D1 and D2), and 
the checkpoint activation genes TP53 and CDKN1A [57]. 
Firstly, we investigated cyclin levels at different time 
points (2, 3 and 5 days after infection) in MCF10DCIS.
com transduced cells. QPCR analysis showed that 
CHD4 depletion decreased mRNA levels of cyclin A2, 
B1 and E2, whereas cyclin D1 and D2 levels were not 
impaired (Figure 4B). PCNA mRNA was also reduced 
to a level similar to cyclin A2 and B1, consistently 
with the observed proliferation arrest (Figure 4B). It is 
known that TP53-CDKN1A axis directly and indirectly 
regulates cell cycle progression [58] and controls G1/S 
transition modulating cyclins levels [59]. Western blot 
analysis performed in MCF10DCIS.com transduced cells 
revealed that the reduction of CHD4 did not increase 
TP53 protein level and its Serine-15 phosphorylation at 
different time points (2, 3 and 5 days after infection), 
but it determined a substantial up-regulation of CDKN1A 
protein level (Figure 4C) since the early time point (2 
days since infection) of the experimental assay. Taken 
together, this data suggest that CHD4 silencing increases 
CDKN1A content, decreases A2, B1 and E2 cyclin 
levels and arrests the cells in the G0/G1 phase of cycle 
Figure 3: CHD4 role in the MMTV-NeuT transgenic mouse and in PDX breast cancer models. A. Cells derived from 
dissociation of spontaneous mammary tumors of MMTV-NeuT mice were infected with two pooled shRNAs silencing Chd4 gene and a 
corresponding control (scramble – SCR) and subsequently transplanted in FVB mice. Box plots represent the tumor volume (mean±SD - 
cm3) of eight to ten distinct tumors grown in vivo. Statistical difference between groups was calculated using Mann-Whitney U test (U=14.0; 
*: P<0.05). Transduced cells were also used to analyze in vitro cell proliferation (eight days) B. and migration C. Statistical significance was 
calculated by applying a Student t-test (*: P<0.05; ***: P<0.001). D. Immunohistochemical staining of Estrogen (ER), Progesterone (PgR), 
HER2+ receptors and Ki67 in three metastatic breast cancer (MBC) patient-derived xenografts (PDXs). Percentage (%) of positive cells is 
reported for each staining. Scale bar: 100μm. E. Box plots representing tumor volume (mean±SD - cm3) of four distinct tumors arisen after 
transplantation of PDXs cells infected with a pool of two shRNAs targeting CHD4 and the corresponding control (shLUC) in NSG mice. 
Statistical significance was calculated by applying a Student t-test (*: P<0.05; **: P<0.01).
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progression rather than inducing apoptosis through the 
activation of caspases (data not shown).
To contextually analyze the effect of CHD4 and its 
putative effectors in breast cancer cell cycle progression, 
we took advantage of a more quantitative and sensitive 
technique, the A.M.I.C.O. (automated microscopy for 
image cytometry) technology, which allowed us to 
perform a multi-parameter analysis, targeting specific 
cell subpopulations [60, 61]. To analyze effects of 
CHD4 downregulation on proliferation ability, cell 
cycle progression and regulation we simultaneously 
assessed the level of i) CHD4, ii) Ethinyl-deoxyUridine 
(EdU), for active DNA synthesis detection, iii) Ki67, as 
a proliferation marker, and iv) TP53 and CDKN1A, to 
monitor checkpoint activation, in relation to DNA content. 
We transiently transfected MCF10DCIS.com cells with 
two different siRNAs targeting CHD4 (siCHD4-1 and 
siCHD4-2), the pool of the two siRNAs (siCHD4-pool) or 
siRNA Luciferase (siLUC) as control. We first confirmed 
that CHD4 was efficiently silenced evaluating its content 
with respect to DNA in different cell populations (siLUC, 
siCHD4-1, siCHD4-2, siCHD4-pool). CHD4 transfected 
cells showed low CHD4 levels in comparison to neutral 
controls (Supplementary Figure S4A, S4B). We evaluated 
DNA profiles and DNA synthesis by EdU content analysis 
in MCF10DCIS.com cells confirming a robust cell 
cycle arrest in the G0/G1 phase of CHD4-silenced cells 
(Figure 5A). Furthermore, loss of CHD4 significantly 
reduced the S phase of breast cancer cells (16-19%) 
(Figure 5A). The effect of CHD4 knock-down on 
proliferative ability of the cells was further confirmed by 
the evaluation of the number of acquired events measured 
as cellular density in all conditions examined. In fact, a 
lower number of events were acquired for CHD4 silenced 
cells due to a reduced proliferative capability (Figure 5A). 
The effect of CHD4 knock-down on proliferation was 
further confirmed by the evaluation of the number of 
acquired events, as a measure of cellular spatial density. 
In fact the imaged area being equal, a lower number of 
events was acquired for CHD4 silenced cells due to a 
reduced capability of these cells to proliferate (Figure 5A). 
In agreement with the above observation, the analysis of 
Ki67 content in the cells interfered for CHD4 (Figure 5B) 
revealed a drastic reduction (25-49%) in the actively 
proliferating fraction compared to control population. 
Arrested cells were blocked in the G0 phase [62] with a 
Figure 4: CHD4 function in MCF10DCIS.com cell cycle progression. A. MCF10DCIS.com cells were infected with shCHD4 
or control (shLUC) and after 5 days analyzed by flow cytometry for Bromodeoxyhuridine (BrDU) and PI content. Percentage (%) of cell 
population in each phase of cell cycle (G0/G1, S and G2/M) is reported within the panels. B. Effect of CHD4 silencing on the regulation of 
different genes controlling cell cycle progression and proliferation was detected by qPCR analysis at different time points (days – d) from 
infection. Histograms represent mRNA levels (mean ± SE of two independent experiments) of cyclin A2, cyclin B1, cyclin D1 and D2, 
cyclin E2, PCNA in MCF10DCIS.com cell line. RPLP0 was used as housekeeper. C. Total TP53, phospho-TP53 (serine15) and CDKN1A 
levels were analyzed, at different time points (days – d) from infection, by western blot in MCF10DCIS.com cells infected with shCHD4 
and the control shLUC. Vinculin was used as normalizer.
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complete exit from cell cycle well before the completion 
of the G1 phase.
Quite strikingly, analysis on TP53 content revealed 
no modification of TP53 level upon CHD4 silencing in 
comparison to control cells (Figure 5C), confirming that 
TP53 is not required to maintain G0 arrest. As a further 
confirmation of this data, the CHD4 knocked down 
population was subdivided in CHD4 positive (CHD4+, 
with CHD4 residual expression) and negative (CHD4-) 
cells. The analysis of TP53 content showed a similar 
distribution in both subpopulations (Supplementary Figure 
S4C).
Figure 5: Cell cycle progression, proliferation index and checkpoint activation analysis by high-content and high-
resolution multiparameter image cytometry. MCF10DCIS.com cells were transfected with two separate (siCHD4-1 and 
siCHD4-2) or pooled (siCHD4-pool) siRNAs against CHD4 or the control (siLUC). DNA content (x-axis) was correlated to the analyzed 
parameter (y-axis): EdU A. Ki67 B. TP53 C. CDKN1A D. content. Percentages of cells in each phase of cell cycle are reported with 
respect to the total cell population (A). Ki67 (B), TP53 (C) and CDKN1A (D) content are expressed as percentage with respect to the 
gated cell population.
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Finally, analysis of CDKN1A levels in 
MCF10DCIS.com cells revealed a strong increase of 
CDKN1A content (45-47%) in the CHD4 depleted 
cells, compared to neutral control (Figure 5D). Almost 
all silenced cells (CHD4-) showed a dramatic up-
regulation of CDKN1A in comparison to CHD4+ cells 
(Supplementary Figure S4D) confirming that the down-
regulation of CHD4 causes a consistent cell cycle arrest 
and a consequent proliferation loss due to a significant 
up-regulation of CDKN1A level.
DISCUSSION
Despite impressive improvements in breast cancer 
survival over the last decades, a not negligible number 
of patients still relapse as consequence of resistance to 
conventional treatment [63]. Therefore, the identification 
of new druggable genes involved in tumorigenesis must 
be considered of utmost importance. Here we show that 
we have identified novel epigenetic targets by means of 
an RNAi screen performed in vivo and in vitro in the 
MCF10DCIS.com cell line.
We took advantage of a published protocol 
in which MCF10DCIS.com cells were screened 
with a metabolic library composed of 516 shRNAs 
[14]. Although we increased the number of shRNAs 
composing each library (see Materials and Methods 
for details), we were able to represent the complexity 
of the system and contextually reduce the possibility of 
detecting false positive depleted genes, as more shRNAs 
were included in the analysis.
Our in vitro and in vivo approach allowed us to 
compare the two conditions and take into considerations 
those genes whose activity interferes with tumor 
growth either in vivo or in vitro. Approximately 50% 
of the genes that we found depleted in the two screens 
were common to the two conditions, suggesting that 
the regulation of epigenetic pathways in breast cancer 
relays on mechanisms that can be uncovered in the 
two contexts. Moreover, IPA showed that a relevant 
proportion of these genes are implicated in the control 
of cell cycle progression.
We have fully validated the epigenetic screens in 
vivo and in vitro by analyzing four different hits and we 
have demonstrated that BAZ1B, BPTF, BRD4 and CHD4 
are essential for breast cancer growth. In particular, it has 
already been demonstrated that CHD4, together with the 
other subunits of the NuRD complex, is implicated in 
tumor progression [32, 48, 64], but up to now no data were 
available in breast cancer. In our system, CHD4 silencing 
significantly reduces cell proliferation and migration both 
in vivo and in vitro, suggesting that CHD4 inhibition can 
be important to block cancer progression.
Because of the complexity and heterogeneity 
of breast cancer, it seems crucial to set up appropriate 
preclinical systems to fully investigate the different 
aspects of this disease. Therefore, an integrated and multi-
systems approach is currently the strongest way to model 
this disease and to study gene vulnerabilities [65].
Since the human in vivo shRNA screen has been 
performed in immunodeficient animals, we investigated 
the role of CHD4 in a model in which tumor develops 
in the presence of an intact immune system. In vivo and 
in vitro silencing of CHD4 in the MMTV-NeuT model 
revealed that it plays a crucial role also in a fully immune-
competent system, meaning that the tumorigenic function 
of CHD4 can bypass the intrinsic immune surveillance. 
Concerning the oncogenic role of CHD4 in HER2+ breast 
cancer, it seems likely that targeting CHD4 in HER2+ 
patients can be a valuable strategy to overcome resistance 
to approved drugs [66–68]. To explore the role of CHD4 
in patients, we used PDX models of Luminal B and Triple 
Negative breast cancer. The dramatic reduction of tumor 
growth induced by the loss of CHD4 is extremely relevant 
and suggests that the pharmacological inhibition of this 
gene could improve the treatment of the most aggressive 
breast cancer subtype.
Despite the high selectivity of targeted therapy, 
unpredictable side effects and toxicity in normal cells can 
emerge [69]. Therefore it is extremely important to test 
the effects of CHD4 silencing on normal cells. We showed 
that CHD4 depletion did not influence the proliferative, 
migratory and clonogenic potential of the non-transformed 
MCF10A cells, suggesting that CHD4 is selectively 
responsible of cell survival and proliferation in cancer 
cells only.
With this work, we shed light on the mechanisms 
through which CHD4 stimulates breast cancer cell 
proliferation. Noticeably, for the first time, we show that 
CHD4 is an essential gene in breast cancer progression. 
In particular, cell cycle analysis showed that the loss 
of CHD4 causes MCF10DCIS.com cells to arrest in G0 
phase, with a dramatic reduction of proliferation and 
a striking reduction of DNA synthesis. Loss of CHD4 
arrested the cells well before the G1/S transition as 
demonstrated by the selective loss of Ki67 prolifera-
tion marker. Differently to U2OS cells, where cycle 
progression is regulated in a TP53-dependent manner 
[33], our results suggest that CHD4 can suppress cell 
cycle progression through CDKN1A up-regulation in 
breast cancer cells.
It has been shown that oncogenic RAS, as well 
as RAF, one of its downstream effectors, activates 
CDKN1A transcription through both TP53-dependent 
and TP53-independent mechanisms, the second 
one requiring the transcription factor E2F1 [70]. 
MCF10DCIS.com cells contain an active HRAS and 
for this reason, the E2F1 binding activity, as well as 
HRAS/CHD4/E2F1 axis, will be actively investigated 
in these cells.
In conclusion, our approach identifies diverse 
epigenetic targets as crucial oncogenes in breast cancer, 
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suggesting in particular that CHD4 targeting can be 
used as an efficient strategy to arrest breast cancer 
progression.
MATERIALS AND METHODS
Libraries and plasmids and siRNAs
Libraries
Human epigenetic libraries were purchased from 
Cellecta Inc. and engineered into the pRSI-U6-(sh)-UbiC-
GFP-2A-Puro lentiviral vector containing the puromycin-
resistance and the GFP fluorescent marker. shRNAs 
were under the control of a constitutive U6 promoter and 
univocally associated to a barcode cassette (BC) of 18 
degenerated, non-overlapping nucleotides. The libraries 
contained 1204 (hEpi1) and 1192 shRNAs (hEpi2) 
targeting 118 (hEpi1, 10 different shRNAs per gene) and 
118 (hEpi2, 9 or 10 different shRNAs per gene) epigenetic 
genes, three positive (KIF11, PSMA1, RPL30) and one 
neutral (Luciferase, LUC) controls.
Plasmids
Each shRNA was cloned into the pRSI-U6-(sh)-
UbiC-TagRFP-2A-Puro vector (Cellecta Inc.) and as 
pool of two shRNAs was used to infect target cells. 
Complete sequences of shRNAs used for validation 
experiments are reported in Supplementary Table S1. 
shRNAs targeting mouse genes were engineered into the 
pLKO.1 vector (Sigma). 3 scrambles shRNAs were pooled 
together and used as neutral control (SCR). The shRNAs 
targeting Chd4 were used as pool of two distinct shRNAs. 
Complete sequences of shRNAs and control are provided 
in Supplementary Table S1.
siRNAs
siMax siRNA 21 mers, obtained from Eurofin 
Genomics, were used for the gene silencing of LUC 
(5’-UACGACGAUUCUGUGAUUU-3’) as control 
and CHD4 (siRNA sequences - siCHD4-1: 5’-CCCAG 
AAGAGGAUUUGUCA-3’ and siCHD4-2: 5’-GGUUU 
AAGCUCUUAGAACA-3’). siRNAs targeting CHD4 
were also used in pool.
Cell cultures and infection
MCF10DCIS.com (obtained from Wayne 
State University, 5057 Woodward Avenue, Detroit - 
Michigan) and MCF10A (obtained from NIH Institute 
and authenticated in house by Gene Print 10 System, 
Promega) cell lines were maintained in their respective 
media as recommended by suppliers. MMTV-NeuT 
cells were obtained from dissociation of tumors 
following protocol described in www.stemcell.com. 
Human metastatic breast cancer (MBC) xenografts were 
obtained by direct implantation of patient-derived tumor 
tissue into the mammary fat pad of NOD.Cg-Prkdcscid 
Il2rgtm1Wjl/SzJ mice (NSG). Patient–derived xenografted 
tumors (PDXs) were then serially re-transplanted to 
generate secondary tumors. PDX cells were obtained 
by enzymatic digestion and mechanical dissociation 
(Miltenyi Biotec) of tumors and grown in culture to 
obtain short-term human cultures. MMTV-NeuT and 
PDX cells were maintained in DMEM/F12 (1:1, Lonza/
Gibco) supplemented with 10% Standard Fetal Bovine 
Serum (FBS) (HyClone, GE Healthcare Life Science), 
10mM HEPES (Sigma), 5 μg/mL insulin (Roche), 0.5 
μg/mL hydrocortisone (Sigma), 20 ng/mL (MMTV-
NeuT cells) or 10 ng/mL (PDXs cells) epidermal growth 
factor (EGF, Tebu-Bio), 10 ng/mL (MMTV-NeuT cells) 
or 50 ng/mL (PDXs cells) Cholera Toxin (Sigma). 
Concentrated lentiviral particles (TU, transducing 
units) from libraries or single plasmids were either 
purchased by Cellecta Inc. or produced by transfecting 
293T cells, as described in the Cellecta User Manual 
(http://www.cellecta.com/wp-content/uploads/Cellecta-
Manual-13Kx13K-Barcode-Library-v1c.pdf). Lentiviral 
particles were added to MCF10DCIS.com, MCF10A, 
MMTV-NeuT or PDX short term cultures, together with 
4 µg/mL polybrene (Sigma) for 16 hours. After 48 hours 
medium was replaced and 3μg/mL of puromycin was 
added for 72 hours before performing the experiments. 
Library infection was performed on MCF10DICS.
com cells using a Multiplicity of Infection (MOI) of 
~0.2 TU/cell. Conversely, in the in vivo validation 
and in vitro studies, cells were infected at high MOI 
(MCF10DCIS.com and MCF10A cells at MOI of ~3, 
MMTV-NeuT at MOI of ~20 and PDX culture cells 
at MOI of ~50 with pooled shRNAs silencing specific 
target genes).
Animals
Non-obese diabetic/severe combined immunodefici-
ency (NOD/SCID) mice and Friend Virus B-Type (FVB) 
were purchased from Harlan Laboratories. NSG mice were 
purchased from Charles River. MMTV-NeuT transgenic 
mice were in the FVB background [71]. Only female 
mice 6-12 weeks old (15-20 gr weight) were used for 
experimental procedures.
Ethics statement
Investigation has been conducted in accordance 
with the ethical standards and according to national and 
international guidelines. In vivo studies were performed 
after approval from our fully authorized animal facility, 
notification of the experiments to the Ministry of Health 
(as required by the Italian Law)(IACUCs Nº 757/2015) 
and in accordance to EU directive 2010/63. Human tissue 
biopsies were collected from patients whose informed 
consent was obtained in writing according to the policies 
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of the Ethics Committee of the European Institute of 
Oncology and regulations of Italian Ministry of Health. 
The studies were conducted in full compliance with the 
Declaration of Helsinki.
In vivo and in vitro shRNA screens
1.2^106 MCF10DCIS.com cells transduced with 
epigenetic libraries were orthotopically injected in the 
4th mammary gland of 12 NOD/SCID mice, or plated 
in duplicate in vitro. Reference cells, cells cultured 
for 21 days [72] and tumors harvested 28 days after 
transplantation [14] were subjected to DNA extraction. 
BCs representation was measured by Next Generation 
Sequencing (NGS) on Illumina HiSeq2000 and BCs 
were identified by aligning each sequencing read to the 
barcoded-libraries using the Bowtie aligner [73], and 
by considering only those BCs having, at most, three 
mismatches in each alignment. Detailed procedures of 
the analysis of the screen are described in Results. gDNA 
extraction, PCR assay and NGS were performed according 
to what reported in the Cellecta User Manual.
In vivo study
MCF10DCIS.com, MMTV-NeuT and PDX cells 
were infected with control shRNA (shLUC) and pooled 
shRNAs silencing specific target genes (see main text). 
2.5^105 infected MCF10DCIS.com or PDX cells and 
5^105 infected MMTV-NeuT cells were orthotopically 
injected into the 4th mammary gland of 4 to 8 mice 
(respectively NOD/SCID, NSG or FVB). Tumor volume 




2^103 MCF10DCIS.com or MCF10A infected cells 
were plated in triplicate (see above) and cell proliferation 
was measured by CellTiter-Glo assay (Promega). 8^104 
MMTV-NeuT infected cells were plated in triplicate and 
counted every 48 hours.
Migration assay
The migration assay was performed using 8.0µm 
pore size inserts in 24-well plates. Triplicates of 2.5^105 
MCF10DCIS.com cells were seeded in the upper chamber 
in 0.5% horse serum and complete medium supplemented 
with 50% FBS were added as chemoattractant in the 
lower chamber [74]. 5^104 overnight starved (1% horse 
serum) MCF10A cells were seeded in the upper chamber 
and complete medium was added in the lower chamber. 
After 24 hours of incubation, migrated cells were fixed 
in 10% methanol and stained with 0.5% Crystal Violet. 
Migration was quantified by ImageJ analysis. Triplicates 
of 1^105 MMTV-NeuT cells in growth factors and serum 
free medium were seeded in the upper chamber and 
complete medium supplemented with 50% FBS was used 
as chemoattractant. After 24 hours of incubation, cell 
migration was quantified as described previously.
Colony formation assay
Clonogenic potential of 1^103 MCF10DCIS.com 
and MCF10A cells was measured in triplicates. After 7 
days of culture, colonies were fixed, stained and counted 
as described above.
Immunohistochemistry
Tumor fragments from PDXs were formalin-fixed 
and paraffin-embedded. After deparaffinization, sections 
were treated with 1 mM EDTA buffer (pH=8) for 30 min at 
95°C, followed by incubation with 3% hydrogen peroxide 
in distilled water for 5 min at RT. Sections were stained 
with monoclonal anti-estrogen (ER) (Dako, clone 1D5); 
monoclonal anti-progesterone (PgR) (Dako, clone PgR 
636); polyclonal anti-ErbB2 (Dako-A0485); monoclonal 
anti-Ki67 (Dako, clone MIB-1). Images were acquired 
by OLYMPUS BX51 up-right (objective UPIanAPO 




5 days post shRNA infection (shLUC and shCHD4), 
MCF10DCIS.com cells were pulsed with 5 mM 
Bromodeoxyuridine (BrdU), fixed and stained against 
BrdU (BD Biosciences). Pellet cells were stained with 
secondary antibody, incubated with propidium iodide (PI) 
and RNaseA and then acquired by fluorescent-activated 
cell sorting (FACS) at FACS Canto II (BD Bioscience). 
Analysis was performed using FlowJo 9.3-2 analysis 
software.
Multiparameter image cytometry
MCF10DCIS.com cells were transfected with siMax 
siRNA 21 mer silencing LUC or CHD4 (as single siRNA: 
siCHD4-1 and siCHD4-2 and pooled siRNA: siCHD4-
pool) using Lipofectamine RNAiMAX reagent (Life 
Technologies, 13778-075). After 72h, cells were pulsed 
with 10 μM EdU (a synthetic nucleotide to identify DNA-
replicating cells), fixed and stained against CHD4 (Sigma-
HPA012008), Ki67 (BD Pharmigen-558615), TP53 
(Santa Cruz-sc6243), CDKN1A (Dako-M7202) and EdU 
(Click-iT™ Imaging kit; Life Technologies), according 
to manufacturer instructions. Images were collected by a 
BX61 fully motorized Olympus fluorescence microscope 
controlled by Scan^R software. An oil immersion 60X 1.3 
NA objective was employed for acquisition. Cell cycle 




Total RNA was extracted from MCF10DCIS.com 
cells infected with shCHD4 and shLUC using the Quick-
RNA MiniPrep kit ZymoResearch and reverse transcribed 
using EasyScript Plus Reverse Transcriptase and 
EasyScript Plus cDNA Synthesis kit. Quantitative RT-PCR 
analyses were done in triplicate on the Applied Biosystems 
7500 Fast Real-Time PCR System with the fast-SYBR 
Green PCR kit as instructed by the manufacturer (Applied 
Biosystems). The transcription level of RPLP0 was used 
as housekeeper.
Western blot analysis
MCF10DCIS.com, MCF10A, MMTV-NeuT and 
PDX cells were lysed in RIPA buffer supplemented with 
protease inhibitors (Roche). Protein extracts were resolved 
on SDS-polyacrylamide gel, blotted onto nitrocellulose 
membranes and probed with antibodies against Vinculin 
(Sigma V9131), BAZ1B (Abcam ab51256), BRD4 
(Abcam ab128874), CHD4 (Abcam ab70469), BPTF 
(Novus Bio-NB100 41418). Membranes were incubated 
with appropriate secondary antibodies linked to horsera-
dish peroxidase. Blots were then developed with the 
ECL system according to manufacturer’s protocols and 
acquired by VueScan 9 x 32 (9.0.89). Images have been 
cropped at specific protein band of interest to improve the 
clarity of data presentation.
Gene set enrichment analysis and protein 
interaction
The list of candidate hits scored in the in vivo and 
in vitro settings was uploaded to the Ingenuity Pathway 
Analysis (IPA) software (Qiagen, Valencia, CA) and IPA 
core analysis was run to analyze pathways and genes 
interaction scoring at high significance. Gene list was also 
investigated in Molecular Signature Data Base, MSigDB 
(http://software.broadinstitute.org/gsea/msigdb/annotate.
jsp), applying “Compute Overlaps” tool and “Hallmark 
gene sets”. Protein interaction network was analyzed via 
online Search Tool for the Retrieval of Interacting Genes 
(STRING v 10.0 http://string-db.org).
Statistical analysis
The correlations between tumors, cells and pools 
in the in vivo and in vitro screen were analyzed by 
Pearson correlation analysis. In vitro and in vivo data are 
presented as the mean ± s.d. (standard deviation) from 
three independent experiments. QPCR data are reported 
as mean ± s.e. (standard error) of two independent 
experiments done in triplicate. Statistical analyses 
were performed using a two-tailed Student’s t-test and 
one way ANOVA plus post-hoc Dunnett’s test. In vivo 
read out of MMTV-NeuT transplantation assay was 
analyzed with a Mann-Whitney U test. Differences were 
considered statistically significant at p<0.05 (*), p<0.01 
(**) and p<0.001 (***).
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